HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Larson, S. M. Search for Related Content PubMed PubMed Citation Articles by Larson, S. M.

Radiolabeled Monoclonal Anti-Tumor Antibodies in Diagnosis and Therapy^*

Department of Nuclear Medicine, the National Institutes of Health, U.S. Public Health Service, Bethesda, Maryland

Correspondence: For reprints contact: Steven M. Larson, MD, Dept. of Nuclear Medicine, 1C401/ACRF, National Institutes of Health, Bestheda, MD 20205.

ABSTRACT

Clinical work with radiolabeled anti-tumor antibodies has made remarkable progress in the past few years. Still, there is much to be done before these new reagents can have a substantial impact on the practical management of patients. In this discussion, the properties of an "ideal" radiolabeled antibody and important factors for in vivo localization in tumors are reviewed. Potential approaches to improving the localization of currently available "tumor specific" monoclonal antibodies are discussed and examples of patients examined and treated with this method are presented. Experience to date suggests that within the foreseeable future, radiolabeled antibody techniques will become a "genuinely decisive technology."

FOOTNOTES

^* Presented as the First Annual SNM Lectureship at the 31st Annual Meeting of the Society of Nuclear Medicine, June 5, 1984, Los Angeles, California.